Investigating new molecules to treat Alzheimer's disease
Official title: Single molecules with multi-mechanistic modes of action as probative anti-Alzheimer’s agents
Funded at University of the Incarnate Word · NIH-10870095 · Data updated 2026-11-12
This study is looking for new ways to help people with Alzheimer's by creating special compounds that can tackle the disease from different angles, aiming to slow down its progress and boost thinking skills.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of the Incarnate Word NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | June 15, 2021 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $99,264 |
| NIH project number | 5SC3GM140980-04 |
| Project ID | NIH-10870095 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 65 and older who are experiencing symptoms of Alzheimer's disease.
✕Less likely to help
Patients with early-stage Alzheimer's or those under 65 years of age may not benefit from this research.
What this research studies
This research focuses on developing new compounds that target multiple mechanisms to combat Alzheimer's disease. The approach involves synthesizing derivatives of a specific molecule, Tubastatin A, and testing their effectiveness in binding to certain receptors and inhibiting a key enzyme associated with neurodegeneration. By exploring these multi-targeted compounds, the research aims to find more effective treatments that could slow the progression of Alzheimer's and improve cognitive function in patients. The study is particularly urgent given the rising number of Alzheimer's cases and the limitations of current treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments that slow the progression of Alzheimer's disease and improve the quality of life for patients.
How similar studies have gone: While there have been various approaches to treating Alzheimer's, this specific multi-targeted strategy is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
-
University of the Incarnate Word
San Antonio, United States Active
Researchers
- Principal investigator: Sikazwe, Donald M — University of the Incarnate Word
- Study coordinator: Sikazwe, Donald M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.